Clinical significance of Y chromosome loss in hematologic disease

Anne Wiktor, Benjamin A. Rybicki, Zhe Si Piao, Muhammad Shurafa, Bernd Barthel, Koichi Maeda, Daniel L. Van Dyke

Research output: Contribution to journalArticle

124 Scopus citations

Abstract

We have studied 215 male patients (aged 45-97 years) whose sole cytogenetic abnormality was clonal loss of the Y chromosome in metaphase cells from unstimulated cultures. The patients comprised a control group with no evidence of hematologic disease and four disease case groups: 1) myelodysplastic syndrome (MDS), refractory anemia, refractory anemia with excess blasts (RAEB), RAEB in transformation, and chronic myelomonocytic leukemia; 2) acute myelogenous leukemia; 3) myeloproliferative disorder (MPD), chronic granulocytic leukemia, and polycythemia vera; and 4) B-cell lymphoma/leukemia. The frequency of cells with Y loss increased with age and was significantly greater in cases than in controls, but it was not correlated with survival or with prior therapy. The frequency of cases with a -Y clone was 6.3% of male karyotypes and represented 16.4% of all abnormal male cytogenetic reports. Much of the difference between cases and controls appears to be accounted for by a greater frequency of cases with > 75% Y loss. A value of 81% chromosome Y loss maximized the combined sensitivity (28%) and specificity (100%) for predicting disease status, but a 75% cutoff provided the best estimate of disease risk. Even in older males, if > 75% of metaphase cells are 45,X,-Y, they probably represent a disease-associated clonal population, and it is possible that the critical genetic change is not visible through the microscope. This observation is true for MDS, MPD, B-cell disease, and especially acute myelogenous leukemia. The prognostic association of Y chromosome loss for survival appears to be neutral or favorable.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalGenes Chromosomes and Cancer
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Wiktor, A., Rybicki, B. A., Piao, Z. S., Shurafa, M., Barthel, B., Maeda, K., & Van Dyke, D. L. (2000). Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes and Cancer, 27(1), 11-16. https://doi.org/10.1002/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I